Ryan & Maniskas, LLP ( www.rmclasslaw.com/cases/adlr) is investigating potential claims against the board of directors of Adolor Corporation ("Adolor" or the "Company") (NASDAQ: ADLR) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Adolor to Cubist Pharmaceuticals, Inc. (“Cubist”) in a transaction valued at approximately $415 million.

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Adolor. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/adlr.

Under the terms of the agreement, Cubist will acquire all outstanding shares of Adolor for $4.25 per share in cash. In addition to the cash payment Adolor shareholders would receive one Contingent Payment Right (“CPR”) entitling the holder to receive additional cash payments of up to $4.50 for each share owned if certain benchmarks are achieved. Under the agreement, Cubist will commence a tender offer to purchase all outstanding shares of Adolor for the upfront cash payment and CPR.

If you own shares of Adolor and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/adlr. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

If you liked this article you might like

Insiders Trading TXI, WFM, ADLR, TRS

Insiders Trading TXI, WFM, ADLR, TRS

10 Best-Performing Stocks Under $5 in 2011

ValueAct Buys $3.9M More of Immucor

ValueAct Buys $3.9M More of Immucor

Health Winners & Losers: Bristol-Myers

Health Winners & Losers: Bristol-Myers

Progenics Has a Few Reasons to Live

Progenics Has a Few Reasons to Live